BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38169559)

  • 21. A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy.
    Huang Z; Li Z; Wang J; Gui R; Zu Y; Yu F; Lin Q; Zhao H; Zhang Y; Fang B; Liu Y; Zhou K; Li Y; Fu Y; Yao Z; Song Y; Zhou J
    Front Oncol; 2023; 13():1162413. PubMed ID: 37256185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas-a single-centre experience in 61 patients.
    Brezina T; von Dewitz H; Schroeder T; Ullrich S; Nachtkamp K; Reifenberger G; Malzkorn B; Sabel M; Haas R; Kobbe G
    Ann Hematol; 2022 Mar; 101(3):607-616. PubMed ID: 34982196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).
    Cho H; Yoon DH; Shin DY; Koh Y; Yoon SS; Kim SJ; Do YR; Lee GW; Kwak JY; Park Y; Kim MK; Kang HJ; Yi JH; Yoo KH; Lee WS; Park BB; Jo JC; Eom HS; Kim HJ; Jeong SH; Won YW; Sohn BS; Kwon JH; Suh C; Kim WS
    Cancer Res Treat; 2023 Apr; 55(2):684-692. PubMed ID: 36596727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
    Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
    J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
    Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
    d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
    J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
    Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
    Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
    Ahn JS; Yang DH; Jung SH; Chae YS; Sohn SK; Yhim HY; Kwak JY; Lee SR; Kim YK; Kim HJ; Lee JJ
    Ann Hematol; 2013 Jun; 92(6):789-97. PubMed ID: 23358616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers.
    Fossard G; Broussais F; Coelho I; Bailly S; Nicolas-Virelizier E; Toussaint E; Lancesseur C; Le Bras F; Willems E; Tchernonog E; Chalopin T; Delarue R; Gressin R; Chauchet A; Gyan E; Cartron G; Bonnet C; Haioun C; Damaj G; Gaulard P; Fornecker L; Ghesquières H; Tournilhac O; da Silva MG; Bouabdallah R; Salles G; Bachy E
    Ann Oncol; 2018 Mar; 29(3):715-723. PubMed ID: 29253087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.
    Kondo E; Ikeda T; Izutsu K; Chihara D; Shimizu-Koresawa R; Fujii N; Sakai T; Kondo T; Kubo K; Kato Y; Akasaka T; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J; Suzuki R;
    Biol Blood Marrow Transplant; 2019 May; 25(5):899-905. PubMed ID: 30664936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
    Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
    Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
    Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis.
    Gui L; Shi YK; He XH; Lei YH; Zhang HZ; Han XH; Zhou SY; Liu P; Yang JL; Dong M; Zhang CG; Yang S; Qin Y
    Int J Hematol; 2014 Jan; 99(1):69-78. PubMed ID: 24258711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Favorable Outcomes with R-CHOP Induction and Consolidative Autologous Stem Cell Transplantation for Double-Hit Lymphoma.
    Puckrin R; Sterrett R; Shafey M; Chua N; Stewart D
    Transplant Cell Ther; 2022 Nov; 28(11):762.e1-762.e4. PubMed ID: 36058549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
    Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
    J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Papajik T; Vondrakova J; Rusinakova Z; Kucerova L; Myslivecek M; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):63-9. PubMed ID: 21475380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical analysis of 25 patients with aggressive peripheral T-cell lymphoma in advanced stage treated with autologous stem cell transplantation].
    Zou D; Huang W; Liu H; Fu M; Li Z; Sui W; Qi J; Zhao Y; Ru K; Han M; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):455-9. PubMed ID: 26134007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.